Treatment of HER2-Positive Metastatic Breast Cancer With Herceptin and Bevacizumab (Antibodies Against HER2 and VEGF)
Status:
Completed
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and effectiveness of combined treatment
with trastuzumab (Herceptin) and bevacizumab (anti-VEGF antibody) in patients with
HER2-positive metastatic breast cancer.